Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 2.670 | -5.32% | -0.150 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | -5.32% | |
| New 52 Week High | Strength | -5.32% | |
| Stochastic Reached Overbought | Strength | -5.32% | |
| Wide Bands | Range Expansion | -5.32% | |
| Above Upper BB | Strength | -5.32% | |
| Overbought Stochastic | Strength | -5.32% | |
| Up 3 Days in a Row | Strength | -5.32% | |
| Up 4 Days in a Row | Strength | -5.32% | |
| Upper Bollinger Band Touch | Strength | -5.32% | |
| Narrow Range Bar | Range Contraction | 9.43% |
| Alert | Time |
|---|---|
| Down 5% | about 1 hour ago |
| Down 3% | about 3 hours ago |
| Down 2% | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: 2024-02-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Cancers Clinical Medicine Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.84 |
| 52 Week Low | 0.215 |
| Average Volume | 178,126 |
| 200-Day Moving Average | 0.789 |
| 50-Day Moving Average | 1.703 |
| 20-Day Moving Average | 2.051 |
| 10-Day Moving Average | 2.333 |
| Average True Range | 0.222 |
| RSI (14) | 74.81 |
| ADX | 34.89 |
| +DI | 42.062 |
| -DI | 11.688 |
| Chandelier Exit (Long, 3 ATRs) | 2.176 |
| Chandelier Exit (Short, 3 ATRs) | 2.065 |
| Upper Bollinger Bands | 2.749 |
| Lower Bollinger Band | 1.353 |
| Percent B (%b) | 1.05 |
| BandWidth | 68.055 |
| MACD Line | 0.254 |
| MACD Signal Line | 0.193 |
| MACD Histogram | 0.061 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.450 | ||||
| Resistance 3 (R3) | 3.387 | 3.113 | 3.345 | ||
| Resistance 2 (R2) | 3.113 | 2.953 | 3.145 | 3.310 | |
| Resistance 1 (R1) | 2.967 | 2.854 | 3.040 | 3.030 | 3.275 |
| Pivot Point | 2.693 | 2.693 | 2.730 | 2.725 | 2.693 |
| Support 1 (S1) | 2.547 | 2.533 | 2.620 | 2.610 | 2.365 |
| Support 2 (S2) | 2.273 | 2.434 | 2.305 | 2.330 | |
| Support 3 (S3) | 2.127 | 2.273 | 2.295 | ||
| Support 4 (S4) | 2.190 |
